SCHEMBL6474335

SCHEMBL6474335

Cc1cccc(-c2ccc(COCCc3cccc(NS(=O)(=O)C(F)(F)F)c3)c(F)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.39
PRMT6 Q96LA8 1/20 0.37
PTGS1 P23219 2/20 0.36
PTGS2 P35354 2/20 0.36
CA2 P00918 2/20 0.36
KIF11 P52732 1/20 0.34
CYSLTR2 Q9NS75 1/20 0.34
CYSLTR1 Q9Y271 1/20 0.34
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
ERAP1 Q9NZ08 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
RAF1 P04049 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481112 0.89 KDM1A (0.41) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6474136 0.89 NAAA (0.40) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6474641 0.89 NAAA (0.40) KDM1APRMT6CA2KIF11ERAP1
SCHEMBL6481745 0.88 EPHX2 (0.41) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6482076 0.88 KDM1A (0.38) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6482230 0.88 KIF11 (0.44) KDM1ACA2KIF11CYSLTR2CYSLTR1
SCHEMBL6482513 0.86 CNR1 (0.39) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6483799 0.83 CA2 (0.39) KDM1APRMT6PTGS1PTGS2CA2
SCHEMBL6474838 0.82 SHMT1 (0.37) KDM1APTGS1PTGS2CA2CYSLTR2
SCHEMBL6479703 0.80 KDM1A (0.45) KDM1APRMT6PTGS1PTGS2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 KDM1A 1124/4885PRMT6 341/4885PTGS1 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.